Interest of monoclonal antibodies in the treatment of ventilator associated pneumonia

Authors

  • Ana Catalina Hernandez Padilla UMR INSERM 1092, Université de Limoges, France1. Inserm CIC 1435, CHU Dupuytren, Limoges, France. 2. UMR INSERM 1092, Université de Limoges, France https://orcid.org/0000-0003-3464-7294
  • Sylvain Meyer 1. UMR INSERM 1092, Université de Limoges, France. 2. Laboratoire de Bactériologie – Virologie – Hygiène, CHU Dupuytren, Limoges, France
  • Bruno François 1. Inserm CIC 1435, CHU Dupuytren, Limoges, France. 2. UMR INSERM 1092, Université de Limoges, France. 3. Réanimation polyvalente, CHU Dupuytren, Limoges, France https://orcid.org/0000-0002-2531-1652

DOI:

https://doi.org/10.37051/mir-00132

Keywords:

monoclonal antibodies, ventilator-associated pneumonia, antibiotics, infection, intensive care unit

Abstract

The development of monoclonal antibodies (mAbs) in infectious diseases has increased in the last 10 years with several therapeutic indications, especially to prevent ventilator associated pneumonia (VAP). The latter remains a major concern in ICUs due to its important incidence, morbidity and related increased mortality. The use of mAbs for this indication has a particular interest, considering their safety profile, developed targets and wide range of intervention opportunities from preemption to adjunctive treatment.

This review aims to look over the main mAbs being tested for the treatment of VAP, their molecular targets and advantages and challenges in their current development.

Image

Downloads

Published

2022-12-23

How to Cite

Hernandez Padilla, A. C., Meyer, S., & François, B. (2022). Interest of monoclonal antibodies in the treatment of ventilator associated pneumonia. Médecine Intensive Réanimation, 31(4), 301–312. https://doi.org/10.37051/mir-00132

Issue

Vol. 31 No. 4 (2022): Octobre-Décembre

Section

Update

Categories